Summary:
Therapeutic Area: Neurology / Depression
Trial Information:
The purpose of this research study is to determine the safety and effectiveness of an experimental study drug in the treatment of depression, also known as major depressive disorder (MDD) compared to placebo (inactive substance) and to evaluate quality of sleep, overall quality of life, and effect if any, on anxiety and satisfaction with the treatment. The drug being studied is a slow release drug (once a day dose used by the body more slowly and steadily) and is one that is not approved by the FDA and is considered investigational.
Total study participation will last up to 19 months and include up to 29 study visits.
Qualified participants will receive study drug in the open label portion of the study (16 – 26 weeks) prior to the double blind placebo controlled portion of the trial, during which each participant will have a 50:50 chance of receiving study drug or placebo.
Eligibility Criteria:
-Age 18-65
-History of depression, either single episode or recurrent episode
Contact Information:
Jennifer Hawkins, RN, CCRC
Palm Beach Neurological Center
3355 Burns Road, Suite 201
Palm Beach Gardens, Fl 33410
(561) 694-1010 Ext. 112 Phone
(561) 694-1360 Fax
e-mail: jhawkinsrn@pbneuro.com
Or you may click "I am interested in this study" below to send message to study coordinator.
Qualified Participants Must:
• Please refer to Study Summary above
Qualified Participants May Receive:
Please refer to Study Summary above